Cerebrospinal fluid τ and β-amyloid(I-42) in dementia disorders

被引：47
|
作者：
Vanmechelen, E
Vanderstichele, H
Hulstaert, F
Andreasen, N
Minthon, L
Winblad, B
Davidsson, P
Blennow, K
机构：
[1] Innogenet NV, B-9052 Ghent, Belgium
[2] Pitea River Valley Hosp, Dept Rehabil, Pitea, Sweden
[3] Malmo Univ Hosp, Neuropsychiat Clin, Dept Clin Neurosci, Malmo, Sweden
[4] Karolinska Inst, Huddinge Univ Hosp, Geriatr Med Sect, Dept Clin Neurosci & Family Med, S-10521 Stockholm, Sweden
[5] Univ Gothenburg, Unit Neurochem, Dept Clin Neurosci, S-41320 Gothenburg, Sweden
来源：
MECHANISMS OF AGEING AND DEVELOPMENT | 2001年 / 122卷 / 16期
关键词：
cerebrospinal fluid; iota; beta-amyloid; Alzheimer's disease; dementia; diagnosis;
D O I：
10.1016/S0047-6374(01)00304-9
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The reliability of cerebrospinal fluid (CSF)-tau and CSF-beta -amyloid assays for diagnosis of Alzheimer's disease and other dementing disorders such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and Creutzfeldt-Jakob disease (CJD) is reviewed. CSF assessment of the two proteins is useful in early diagnosis of AD and to differentiate it from FTD and DLB. Extremely high CSF-tau levels can discriminate CJD from AD. (C) 2001 Elsevier Science Ireland Ltd, All rights reserved.
引用
收藏
页码：2005 / 2011
页数：7
相关论文
共 50 条
  • [31] Matrix metalloproteinases-2 and-3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels
    Mlekusch, Reinhilde
    Humpel, Christian
    NEUROSCIENCE LETTERS, 2009, 466 (03) : 135 - 138
  • [32] Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders - A Pilot Study
    Muller, Mareike
    Claassen, Jurgen A.
    Kuiperij, H. Bea
    Verbeek, Marcel M.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 46 (03) : 605 - 609
  • [33] Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease
    Tapiola, T
    Pirttilä, T
    Mikkonen, M
    Mehta, PD
    Alafuzoff, I
    Koivisto, K
    Soininen, H
    NEUROSCIENCE LETTERS, 2000, 280 (02) : 119 - 122
  • [34] Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
    Dumurgier, Julien
    Schraen, Susanna
    Gabelle, Audrey
    Vercruysse, Olivier
    Bombois, Stephanie
    Laplanche, Jean-Louis
    Peoc'h, Katell
    Sablonniere, Bernard
    Kastanenka, Ksenia V.
    Delaby, Constance
    Pasquier, Florence
    Touchon, Jacques
    Hugon, Jacques
    Paquet, Claire
    Lehmann, Sylvain
    ALZHEIMERS RESEARCH & THERAPY, 2015, 7
  • [35] Unbiased estimates of cerebrospinal fluid β-amyloid 1-42 cutoffs in a large memory clinic population
    Bertens, Daniela
    Tijms, Betty M.
    Scheltens, Philip
    Teunissen, Charlotte E.
    Visser, Pieter Jelle
    ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [36] False Recognition Correlates with Amyloid-β1-42 but not with Total Tau in Cerebrospinal Fluid of Patients with Dementia and Mild Cognitive Impairment
    Hildebrandt, Helmut
    Haldenwanger, Andreas
    Eling, Paul
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (01) : 157 - 165
  • [37] The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations
    Gooblar, Jonathan
    Carpenter, Brian D.
    Coats, Mary A.
    Morris, John C.
    Snider, B. Joy
    ALZHEIMERS & DEMENTIA, 2015, 11 (05) : 533 - 540
  • [38] Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation
    Ernst, Andrea
    Morgenthaler, Nils G.
    Buerger, Katharina
    Dodel, Richard
    Noelker, Carmen
    Sommer, Norbert
    Schwarz, Markus
    Koehrle, Josef
    Bergmann, Andreas
    Hampel, Harald
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 189 (1-2) : 169 - 174
  • [39] Marked increase of β-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury
    Olsson, A
    Csajbok, L
    Öst, M
    Höglund, K
    Nylén, K
    Rosengren, L
    Nellgård, B
    Blennow, K
    JOURNAL OF NEUROLOGY, 2004, 251 (07) : 870 - 876
  • [40] Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?
    Weston, Philip S. J.
    Paterson, Ross W.
    Dickson, John
    Barnes, Anna
    Bomanji, Jamshed B.
    Kayani, Irfan
    Lunn, Michael P.
    Mummery, Catherine J.
    Warren, Jason D.
    Rossor, Martin N.
    Fox, Nick C.
    Zetterberg, Henrik
    Schott, Jonathan M.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (04) : 1297 - 1302
12345